Favourable prognostic factors in therapy related acute myeloid leukaemia

Srp Arh Celok Lek. 2011 May-Jun;139(5-6):347-52. doi: 10.2298/sarh1106347a.

Abstract

Introduction: Therapy related acute myeloid leukaemia (t-AML) is a distinct clinical entity recognized by the World Health Organization classification occurring after chemotherapy and/or radiation treatment administered for a previous disease. T-AML is characterised by pancytopenia, three-lineage myelodysplasia, high frequency of unfavourable cytogenetics and short survival.

Objective: The aim of this study was to analyse clinical, cytogenetic, and cytological characteristics of t-AML and their impact on survival.

Methods: Seventeen patients with t-AML (8 male and 9 female; median age 59 years) were identified among 730 consecutive patients with acute myeloid leukaemia. The degree of three-lineage dysplasia as well as haematological, cytological and cytogenetic analyses, were assessed by standard methods.

Results: The patients survived a median of 62.5 days with the 10% probability of survival during two years. Prognostically favourable factors were a higher percentage of dysplastic granulocytic cells, age less than 60 years, and presence of prognostically favourable karyotype inv(16), t(15;17), t(8;21).

Conclusion: The stated prognostic factors that include age, cytogenetics findings and granulocytic dysplasia analysis could contribute to adequate risk stratification of t-AML, though fuller results would require additional analyses.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / adverse effects
  • Bone Marrow / pathology
  • Cytogenetic Analysis
  • Female
  • Granulocytes / pathology
  • Humans
  • Karyotyping
  • Leukemia, Myeloid, Acute / etiology
  • Leukemia, Myeloid, Acute / genetics
  • Leukemia, Myeloid, Acute / mortality
  • Leukemia, Myeloid, Acute / pathology*
  • Male
  • Middle Aged
  • Neoplasms, Second Primary / etiology
  • Neoplasms, Second Primary / genetics
  • Neoplasms, Second Primary / mortality
  • Neoplasms, Second Primary / pathology*
  • Prognosis
  • Radiotherapy / adverse effects
  • Survival Rate

Substances

  • Antineoplastic Agents